Overview

Phase Ⅲ Clinical Trial of Buagafuran Capsules in the Treatment of GAD

Status:
RECRUITING
Trial end date:
2027-06-30
Target enrollment:
Participant gender:
Summary
A placebo-controlled superiority design was used to evaluate the efficacy of 60-120 mg/ day of Buagafuran capsules in the treatment of GAD.
Phase:
PHASE3
Details
Lead Sponsor:
Beijing Union Pharmaceutical Factory Ltd
Collaborator:
R&G Pharma Studies Co.,Ltd.
Treatments:
buagafuran
Buspirone
Tablets
tebufenozide